Cencora Inc., a global pharmaceutical solutions organization, has announced it will provide logistics and distribution services to support the commercial launch of Precigen Inc.'s newly approved immunotherapy in the United States. The therapy, recently approved by the U.S. Food and Drug Administration, is a non-replicating adenoviral vector-based immunotherapy indicated for adult patients with recurrent respiratory papillomatosis. Under the agreement, Cencora will deliver integrated order-to-cash, third-party logistics, and specialty logistics services-including temperature-controlled storage and distribution. The partnership aims to streamline processes for healthcare providers and ensure secure, timely delivery of the therapy to sites of care.